Hallucinogens, amphetamines, and entactogens;Halluzinogene, amphetamine und entactogene

Therapeutische Umschau

Volumn 60, Issue 6, 2003, Pages 323-328

  Vollenweider, F X ^a   Vollenweider Scherpenhuyzen, M F I ^b  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b KLINIK HIRSLANDEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE DERIVATIVE; CANNABIS; LYSERGIDE; PSILOCYBINE; PSYCHEDELIC AGENT;

BEHAVIOR; DRUG ABUSE; DRUG EFFECT; DRUG USE; HUMAN; MUSHROOM; NEUROTOXICITY; REVIEW; RISK ASSESSMENT;

EID: 0037937393     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.60.6.323     Document Type: Review

References (27)

1. Vollenweider FX, Geyer MA. A systems model of altered consciousness: Integrating natural and drug-induced psychoses. Brain Res Bull 2001; 56 (5): 495-507.
2. Leuner H. Halluzinogene: Psychische Grenzzustände in Forschung und Therapie. 1 ed. Bern: Hans Huber, 1981: 1-459.
3. Strassman RJ. Hallucinogenic drugs in psychiatric research and treatment. Perspectives and prospects. J Nerv Ment Dis 1995; 183 (3): 127-38.
4. Drogenkonsum in der Partyszene: Entwicklungen und aktueller Kenntnisstand. Band 19. Herausgeber: Bundeszentrale für gesundheitliche Aufklärung (BZgA), Köln, 2002: 1-253.
5. Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 1998; 9: 3897-902.
6. Vollenweider FX, Vontobel P, Hell D, Leenders KL. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man: A PET study with [11C]raclopride. Neuropsychopharmacol 1999; 20 (5): 424-33.
7. Hofmann A, Heim R, Brack A, Kobel H, Frey A, Ott H et al. Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen. Helv Chim Acta 1959; 42: 1557-72.
8. Gartz J. Narrenschwämme - Psychotrope Pilze in Europa. 1 ed. Neu Allschwil/Basel: Edition Heuwinkel, 1993: 1-136.
9. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-8.
10. Burns RS, Lerner RS. The effects of PCP in man: A review. In: Domino EF, editor. PCP (Phencyclidine): Historical and Current Perspectives. Ann Arbor: NPP Books, 1981: 449-69.
11. Ghoneim MM, Hinrichs JV, Mewaldt SP, Petersen RC. Ketamine: Behavioral effects of subanesthetic doses. J Clin Psychopharmacol 1985; 5: 70-7.
12. Hansen G, Jensen SB, Chandresh L, Hilden T. The psychotropic effect of ketamine. J Psychoactive Drugs 1988; 20: 419-25.
13. Rätsch C. Enzyclopädie der psychoaktiven Pflanzen. Aarau: AT-Verlag, 1998: 1-941.
14. Waser PG. The pharmacology of amanita muscaria. In: Efron DH, editor. Ethnopharmacologic search for psychoactive drugs. New York: Raven Press, 1979: 419-39.
15. Lieberman JA, Kinon BJ, Loebel AD. Dopaminergic mechanism in idiopathic and drug-induced psychosis. Schizophr Bull 1990; 16: 97-109.
16. Schiorring E. Psychopathology induced by "speed drugs". Pharmacol Biochem Behav 1981; 14: 109-22.
17. Shulgin AT. The background and chemistry of MDMA. J Psychoactive Drugs 1986; 18: 291-304.
18. Liechti ME, Vollenweider FX. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol Clin Exp 2001; 16: 589-98.
19. Dinse H. Ecstasy (MDMA)-Intoxikation, ein Überblick. Anaesthesist 1997; 46: 697-703.
20. Thomasius R, Schmolke M, Kraus D. MDMA («Ecstasy»)-Konsum - ein Überblick zu psychiatrischen und medizinischen Folgen. Fortschr Neurol Psychiat 1997; 65: 49-61.
21. Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology 2001; 154: 161-8.
22. Derlet RW, Rice P, Horowitz BZ, Lord RV. Amphetamine toxicity: experience with 127 cases. J Emerg Med 1989; 7(2): 157-61.
23. Callaway CW, Clark RF. Hyperthermia in psychostimulant overdose. Ann Emerg Med 1994; 24 (1): 68-76.
24. Williams H, Dratcu L, Taylor R, Roberts M, Oyefeso A. "Saturday night fever": ecstasy related problems in a London accident and emergency department. J Accid Emerg Med 1998; 15: 322-6.
25. Vollenweider-Scherpenhuyzen MFI, Vollenweider FX. Emergency cases in drug abuse (Notfälle bei Drogenmissbrauch). Der Internist 2000; 41 (9): 886-98.
26. Cohen S. Lysergic acid diethylamide: Side effects and complications. J Nerv Ment Dis 1960; 130: 30-40.
27. Pearlson GD. Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. John Hopkins Med J 1981; 148: 25-33.